Association between Clostridioides difficile infection and multidrug-resistant organism colonization or infection among hospitalized adults: A case-control study

Jain, Eisha; Shin, Jae Hyun; Wells, Kristen; Pannone, Aaron; Hornsby, Paige P.; Warren, Cirle A.

doi:10.1016/j.ajic.2020.01.008

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other risk factors include being over 65 years of age and having a weakened immune system 7. CDI is typically treated with antibiotics7; however, this can lead to the development of MDROs, that is, to bacteria that have developed a resistance to antibiotics 8. Resistant bacteria make it difficult to combat infection and treat patients effectively and efficiently 9…”

Section: Introductionmentioning

confidence: 99%

“…7 CDI is typically treated with antibiotics 7 ; however, this can lead to the development of MDROs, that is, to bacteria that have developed a resistance to antibiotics. 8 Resistant bacteria make it difficult to combat infection and treat patients effectively and efficiently. 9 Approximately 20% to 30% of antibioticassociated diarrhea is caused by CDI, and among hospitalized patients the rate of recurrence is high, ranging from 20% after the first episode to between 45% and 60% after the second.…”

mentioning

confidence: 99%

See 1 more Smart Citation

CE: Current and Emerging Applications of Fecal Microbiota Transplantation

Baker,

Poole

2023

AJN, American Journal of Nursing

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) is a life-changing treatment for people with recurrent Clostridioides difficile infection (rCDI). Frequently acquired in the hospital, CDI can cause serious gastrointestinal symptoms, including persistent watery diarrhea, abdominal pain, and severe dehydration. Antibiotics, the primary treatment, can unfortunately disrupt the gut microbiome and lead to antimicrobial resistance. FMT involves introducing stool from a healthy donor into the affected recipient to strengthen their compromised microbiome. Individuals receiving this treatment have reported remarkable improvement in clinical outcomes and quality of life. In addition to a discussion of rCDI within the context of the gastrointestinal microbiome, this article provides an overview of the FMT procedure, discusses nursing management of individuals undergoing FMT, and highlights emerging applications beyond rCDI. A case scenario is also provided to illustrate a typical trajectory for a patient undergoing FMT.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%